EVG Stock Overview
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evgen Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.008 |
| 52 Week High | UK£0.041 |
| 52 Week Low | UK£0.007 |
| Beta | 1.44 |
| 1 Month Change | -8.57% |
| 3 Month Change | -56.76% |
| 1 Year Change | -78.95% |
| 3 Year Change | -89.87% |
| 5 Year Change | -96.44% |
| Change since IPO | -97.72% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Oct 11
We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely
Nov 24Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation
Aug 06Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?
Apr 09We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate
Dec 25Shareholder Returns
| EVG | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.2% | -0.4% | 2.2% |
| 1Y | -78.9% | -29.1% | 0.9% |
Price Volatility
| EVG volatility | |
|---|---|
| EVG Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Huw Jones | evgen.com |
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company’s lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues.
Evgen Pharma plc Fundamentals Summary
| EVG fundamental statistics | |
|---|---|
| Market cap | UK£3.42m |
| Earnings (TTM) | -UK£3.35m |
| Revenue (TTM) | UK£838.00k |
4.1x
P/S Ratio-1.0x
P/E RatioIs EVG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVG income statement (TTM) | |
|---|---|
| Revenue | UK£838.00k |
| Cost of Revenue | UK£5.17m |
| Gross Profit | -UK£4.33m |
| Other Expenses | -UK£974.00k |
| Earnings | -UK£3.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0078 |
| Gross Margin | -516.35% |
| Net Profit Margin | -400.12% |
| Debt/Equity Ratio | 0% |
How did EVG perform over the long term?
See historical performance and comparison